Logo image of PHARM.AS

PHARMING GROUP NV (PHARM.AS) Stock Price, Quote, News and Overview

AMS:PHARM - Euronext Amsterdam - NL0010391025 - Common Stock - Currency: EUR

0.745  +0.01 (+1.22%)

PHARM.AS Quote, Performance and Key Statistics

PHARMING GROUP NV

AMS:PHARM (4/25/2025, 7:00:00 PM)

0.745

+0.01 (+1.22%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.97
52 Week Low0.65
Market Cap50.95M
Shares68.39M
Float67.38M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE42.5
Earnings (Next)05-08 2025-05-08
IPO07-02 1998-07-02


PHARM.AS short term performance overview.The bars show the price performance of PHARM.AS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10

PHARM.AS long term performance overview.The bars show the price performance of PHARM.AS in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of PHARM.AS is 0.745 EUR. In the past month the price decreased by -8.14%. In the past year, price decreased by -17.22%.

PHARMING GROUP NV / PHARM Daily stock chart

PHARM.AS Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.11 285.16B
AMG.DE AMGEN INC 14.09 131.97B
GIS.DE GILEAD SCIENCES INC 22.32 112.70B
VX1.DE VERTEX PHARMACEUTICALS INC 1723.6 110.78B
ARGX.BR ARGENX SE 352.5 32.72B
22UA.DE BIONTECH SE-ADR N/A 24.54B
IDP.DE BIOGEN INC 7.17 15.20B
0QF.DE MODERNA INC N/A 9.45B
1MRNA.MI MODERNA INC N/A 9.08B
BIO.DE BIOTEST AG 24.8 1.68B
GLPG.AS GALAPAGOS NV N/A 1.54B
BIO3.DE BIOTEST AG-VORZUGSAKTIEN 17.54 1.19B

About PHARM.AS

Company Profile

PHARM logo image Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Company Info

PHARMING GROUP NV

Darwinweg 24

Leiden ZUID-HOLLAND NL

Employees: 382

Company Website: https://www.pharming.com/

Investor Relations: https://www.pharming.com/investors/upcoming-events

Phone: 31715247400

PHARMING GROUP NV / PHARM.AS FAQ

What is the stock price of PHARMING GROUP NV today?

The current stock price of PHARM.AS is 0.745 EUR. The price increased by 1.22% in the last trading session.


What is the ticker symbol for PHARMING GROUP NV stock?

The exchange symbol of PHARMING GROUP NV is PHARM and it is listed on the Euronext Amsterdam exchange.


On which exchange is PHARM.AS stock listed?

PHARM.AS stock is listed on the Euronext Amsterdam exchange.


What is the price forecast or stock price prediction for PHARMING GROUP NV stock?

14 analysts have analysed PHARM.AS and the average price target is 7.01 EUR. This implies a price increase of 840.82% is expected in the next year compared to the current price of 0.745. Check the PHARMING GROUP NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PHARMING GROUP NV worth?

PHARMING GROUP NV (PHARM.AS) has a market capitalization of 50.95M EUR. This makes PHARM.AS a Micro Cap stock.


How many employees does PHARMING GROUP NV have?

PHARMING GROUP NV (PHARM.AS) currently has 382 employees.


What are the support and resistance levels for PHARMING GROUP NV (PHARM.AS) stock?

PHARMING GROUP NV (PHARM.AS) has a support level at 0.69 and a resistance level at 0.76. Check the full technical report for a detailed analysis of PHARM.AS support and resistance levels.


Is PHARMING GROUP NV (PHARM.AS) expected to grow?

The Revenue of PHARMING GROUP NV (PHARM.AS) is expected to grow by 9.22% in the next year. Check the estimates tab for more information on the PHARM.AS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PHARMING GROUP NV (PHARM.AS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PHARMING GROUP NV (PHARM.AS) stock pay dividends?

PHARM.AS does not pay a dividend.


When does PHARMING GROUP NV (PHARM.AS) report earnings?

PHARMING GROUP NV (PHARM.AS) will report earnings on 2025-05-08.


What is the Price/Earnings (PE) ratio of PHARMING GROUP NV (PHARM.AS)?

PHARMING GROUP NV (PHARM.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).


PHARM.AS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PHARM.AS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to PHARM.AS. While PHARM.AS seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHARM.AS Financial Highlights

Over the last trailing twelve months PHARM.AS reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -2.96%
ROE -5.36%
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%225%
Sales Q2Q%14.1%
EPS 1Y (TTM)-50%
Revenue 1Y (TTM)21.15%

PHARM.AS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 89% to PHARM.AS. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 183.09% and a revenue growth 9.22% for PHARM.AS


Ownership
Inst Owners15.1%
Ins Owners1.49%
Short Float %N/A
Short RatioN/A
Analysts
Analysts88.57
Price Target7.01 (840.94%)
EPS Next Y183.09%
Revenue Next Year9.22%